• Explore /
  • Poster
  • / Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Abstract Poster

Authors

null

Robin Kate Kelley

University of California San Francisco, San Francisco, CA

Robin Kate Kelley , Emily Mitchell , Spencer Behr , Jimmy Hwang , Bridget Keenan , Sarah E Umetsu , John Dozier Gordan , Andrew H. Ko , Pelin Cinar , Chloe Evelyn Atreya , Katherine Van Loon , Thomas Weber , Zoe Ngo , Zoe E. Quandt , Chienying Liu , Alan P. Venook , Lawrence Fong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02703714)

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4087)

DOI

10.1200/JCO.2018.36.15_suppl.4087

Abstract #

4087

Poster Bd #

276

Abstract Disclosures

Similar Posters

First Author: Robin Kate Kelley

First Author: Robin Kate Kelley

First Author: Hazel Lote

First Author: Nicholas Coupe